DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/k7lbzb/eluxadoline) has announced the addition of the "Eluxadoline (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023" report to their offering.
Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.
Eluxadoline is being developed for the treatment of IBS-D. As of October 2014, it had reached the Phase III stage of development, and also has been granted a Fast-Track designation by the FDA. Furiex Pharmaceuticals initially licensed eluxadoline from Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson [J&J]) for the development of the product. Subsequently, Furiex was fully-acquired by Actavis in July 2014 (Furiex Pharmaceuticals, press release, July 2, 2014).
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
3.1 Etiology and Pathophysiology
3.5 Quality of Life
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.2 Treatment Guidelines and Leading Prescribed Drugs
4.1.3 Clinical Practice
5 Competitive Assessment
6 Unmet Need and Opportunity
6.2 More Effective Pharmacotherapies
6.3 Therapies for the IBS-D Subtype
6.4 Therapies for the IBS-M Subtype
6.5 Therapies to Address Abdominal Pain and Bloating Symptoms
6.6 Improved Diagnosis Rate for IBS
7 Pipeline Assessment
7.2 Promising Drugs in Clinical Development
For more information visit http://www.researchandmarkets.com/research/k7lbzb/eluxadoline